Trials / Completed
CompletedNCT00163189
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
Evolution Of Growth Rate In Children With Growth Retardation Related To Long-term Corticotherapy And Treated By Genotonorm
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatropin | Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2005-09-13
- Last updated
- 2024-02-21
- Results posted
- 2015-06-25
Locations
19 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00163189. Inclusion in this directory is not an endorsement.